MB21D2

Across TCGA pan-cancer cohorts, MB21D2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MB21D2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MB21D2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MB21D2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where MB21D2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.647	0.446	.012	30	view →
CCRCC	OS	Median	IV	0.789	0.199	.025	6	view →
LUAD	OS	Quartile	II,III,IV	0.840	1.000	.020	5	view →
GBM	DFS	Tertile	All	0.776	0.652	.027	4	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MB21D2–PDAC (OS)

Open the PDAC breakdown →